Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

NCT05601440 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

484

Enrollment

NETWORK

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: RP-6306
DRUG: Gemcitabine
OTHER: Observation
DRUG: Niraparib
DRUG: Fulvestrant
DRUG: RP-3500
DRUG: CFI-402257
DRUG: CFI-400945
DRUG: Sacituzumab govitecan

Sponsor

Canadian Cancer Trials Group